About Foxo4-DRI
D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"
FOXO4-DRI is a synthetic D-amino acid retro-inverso (DRI) peptide that disrupts the interaction between the FOXO4 transcription factor and p53 in senescent cells, triggering apoptosis selectively in cells with an activated senescent secretory phenotype (SASP) while sparing non-senescent cells in which this interaction is not tonically antiapoptotic. In senescent cells, overexpressed FOXO4 sequesters p53 in the nucleus and prevents it from initiating apoptosis, enabling the persistence of metabolically active senescent cells that secrete pro-inflammatory SASP cytokines; FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, freeing p53 to activate its apoptotic transcriptional program specifically in cells where the FOXO4 sequestration is functionally relevant. The foundational study published in Cell demonstrated that FOXO4-DRI selectively induced apoptosis in senescent cells in vivo in mice, restoring tissue homeostasis in both chemotherapy-induced and naturally aged animals; subsequent molecular modeling work has characterized the FOXO4-TP53 interaction interface to guide further senolytic peptide design, though published evidence in humans is absent and the preclinical literature remains limited. FOXO4-DRI is a research compound with no regulatory approval in any jurisdiction; it has been studied only in preclinical animal models, and no human pharmacokinetic, safety, or clinical efficacy data has been established.
Foxo4-DRI Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Senolytic D-retro-inverso Foxo4 peptide (de Keizer lab, Netherlands). Eliminates p21-positive senescent cells. No FDA approval, no IND or NDA. Novel research compound only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
3 sources cited · 1 strong · 2 moderate
1 Review · 2 Animals
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Cell · 2017
This landmark study demonstrated that FOXO4-DRI, a rationally designed peptide that disrupts the FOXO4-p53 interaction in senescent cells, induced selective apoptosis of senescent cells in aged mice, restoring physical fitness, fur density, and renal function while sparing non-senescent cells, establishing proof-of-concept for peptide-based senolytic therapy.
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.
Naunyn Schmiedebergs Arch Pharmacol · 2026
# Summary Research found that FOXO4-DRI, a senolytic peptide designed to disrupt the FOXO4-p53 complex, selectively eliminates senescent cells in the brain while preserving healthy tissue, thereby reducing accumulation of aging cells and restoring blood-brain barrier integrity, cerebral blood flow, and cognitive function in aged animal models. This study demonstrated that targeting the FOXO4-p53 axis represents a potential pharmacological strategy to address age-related cognitive decline and neurodegenerative conditions by reducing neuroinflammation, synaptic dysfunction, and impaired neurogenesis associated with cellular senescence in the aging brain.
Rational design of a peptide inducing selective apoptosis of p53-high senescent cells by targeting the FOXO4-TP53 protein-protein interaction
EBioMedicine · 2021
Research applying rational peptide design principles to the FOXO4-TP53 interaction produced the ES2 senolytic variant, which selectively cleared p53-high senescent cancer and aged liver cells in mouse models while leaving non-senescent cells intact, extending the therapeutic framework established for FOXO4-DRI.
Foxo4-DRI Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Foxo4-DRI — Providers & Availability
12 providersClinics
5 providersStay updated on verified Foxo4-DRI providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Foxo4-DRI
FOXO4-DRI is a synthetic D-amino acid retro-inverso (DRI) peptide that disrupts the interaction between the FOXO4 transcription factor and p53 in senescent cells, triggering apoptosis selectively in cells with an activated senescent secretory phenotype (SASP) while sparing non-senescent cells in which this interaction is not tonically antiapoptotic. In senescent cells, overexpressed FOXO4 sequesters p53 in the nucleus and prevents it from initiating apoptosis, enabling the persistence of metabolically active senescent cells that secrete pro-inflammatory SASP cytokines; FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, freeing p53 to activate its apoptotic transcriptional program specifically in cells where the FOXO4 sequestration is functionally relevant.
senescent cell clearance, tissue rejuvenation, healthspan extension, senolytic.
Research on Foxo4-DRI primarily documents effects related to senescent cell clearance and tissue rejuvenation and healthspan extension and senolytic. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Foxo4-DRI include active cancer treatment, unknown long-term safety. This is educational information only — consult a qualified healthcare professional before use.
12 providers in the directory currently offer Foxo4-DRI.
This landmark study demonstrated that FOXO4-DRI, a rationally designed peptide that disrupts the FOXO4-p53 interaction in senescent cells, induced selective apoptosis of senescent cells in aged mice, restoring physical fitness, fur density, and renal function while sparing non-senescent cells, establishing proof-of-concept for peptide-based senolytic therapy.